US FDA issues complete response letter to Schering-Plough for Saphris
Saturday, January 17, 2009 16:00 IST Kenilworth, New Jersey
Schering-Plough Corporation announced that the US Food and Drug Administration (FDA) has issued a complete response letter for Saphris (asenapine) sublingual tablets in the acute treatment of schizophrenia